LYCOS RETRIEVER 
Remicade: Patients
built 654 days ago
Remicade is not related to the arthritis drug, Vioxx, a type of medication known as a COX–2 inhibitor that has been linked to an increased risk of heart attacks and strokes. However, a search of FDA documents reveals that in October, 2001, Centocor issued a warning to doctors about patients with congestive heart failure who were taking Remicade for Crohn’s disease or rheumatoid arthritis. In a clinical trial among 150 patients with congestive heart failure, 101 took Remicade and 49 took a placebo. Seven of those taking Remicade died compared with no deaths among the control group. As a result, the letter warned: “Do not initiate [Remicade] therapy in patients with congestive heart failure.” The Remicade prescribing information ... warns about other possible side effects of the drug, including serious infections, allergic reactions, and lupus–like symptoms (chest discomfort, a rash that increases in the sun, and shortness of breath).
Source:
Centocor’s failure to identify and acknowledge the potentially fatal side effects of Remicade demonstrates its indifference toward safeguarding patient safety. Often drug companies are negligent and do not fully inform doctors and patients about the harmful side effects of their drugs. Centocor’s disregard for their consumers’ well-being has made them potentially liable for any illness or death caused by Remicade. The Law Offices of Aylstock, Witkin, Kreis & Overholtz boast some of the most experienced personal injury attorneys in the United States. Contact the attorneys of Aylstock, Witkin, Kreis & Overholtz today at (877) 810-4808 to learn more about your rights if you develop cancer or a serious infection due to using Remicade.
Source:
Evidence of Remicade and skin problems first surfaced in April 2005, when Dutch researchers reported their clinical findings in the medical journal Arthritis Research and Therapy. Remicade works by suppressing the immune system. This is helpful to patients whose overactive immune reactions underlie their rheumatoid arthritis, Crohn's disease, or ankylosing spondylitis, but it can ... be a problem. New evidence, published in May 2006 in the Journal of the American Medical Association, suggests that Remicade can TRIPLE the risk of skin cancer. While previous studies indicated the increased risk of infection and lymphoma, a blood cancer, this is the first study to show that Remicade can cause skin cancer.
Source:
Remicade (Infliximab) is an immune-suppressing drug used to treat rheumatoid arthritis and Crohn's disease. In November of 1999, the FDA approved Remicade (infliximab) to treat rheumatoid arthritis. The problem with Remicade is that it acts as an immune suppressant. This makes patients who take Remicade extremely vulnerable to opportunistic infections, including tuberculosis and sepsis.
Source:
Remicade is a monoclonal antibody used along with methotrexate to reduce inflammation and other symptoms associated with moderate to severe rheumatoid arthritis. Remicade is ... used to treat the signs and symptoms of ankylosing spondylitis, psoriatic arthritis, and certain types of severe skin psoriasis. Remicade is used to reduce symptoms of moderate to severe Crohn disease or ulcerative colitis in patients who have not received relief from other treatments. Remicade may also be used to treat other conditions as determined by your doctor.
Source:
Remicade and Humira pose the risk of localized skin reactions at the injection site. These drugs can ... pose more serious skin-related risks. In 2005, Dutch researchers publishing in the Arthritis Research and Therapy found that Remicade and Humira double the risk of skin infections, skin eruptions, eczema, and more. Moreover, approximately one in four patients taking one of these medications sought medical condition for a Remicade skin side effect within two years of using the drug.
Source:
MORE ABOUT
Patients